MinuteClinic salutes nurse practitioners
MINNEAPOLIS CVS Caremark’s MinuteClinic is saluting nurse practitioners nationwide in celebration of National Nurse Practitioner Week, Nov. 8 to 14.
MinuteClinic is one of the largest employers of nurse practitioners in the nation. The company’s nurse practitioners and physician assistants serve patients at about 500 MinuteClinic locations in select CVS stores in 25 states.
“Our practitioners do a fantastic job with patient education which has allowed the MinuteClinic model to evolve beyond acute care to include wellness and prevention services,” stated Andrew Sussman, M.D., president of MinuteClinic. “We will continue to call on their training and expertise to expand our offerings into disease management services for chronic conditions like diabetes, hypertension and hyperlipidemia.”
Since MinuteClinic launched the nation’s first retail clinics in 2000 its practitioners have provided care for more than five million patient visits.
“Nurse practitioners and physician assistants help Americans live better lives by achieving better health,” stated Donna Haugland, RN, CNP, chief nursing officer of MinuteClinic. “We are proud to work with these professional organizations and academic institutions throughout the country to develop educational programs, training and research that helps grow the profession so even more Americans can experience the great care and treatment nurse practitioners and physician assistants provide.”
FDA approves generic gastroesophageal reflux disease treatments
PITTSBURGH The Food and Drug Administration has given two companies approval for a generic version of a drug used to treat gastroesophageal reflux disease.
Teva Pharmaceutical Industries and Matrix Labs – the Indian subsidiary of U.S. drug maker Mylan – received approval for manufacturing lansoprazole delayed-release capsules. The drug is a generic version of Tap Pharmaceuticals’ Prevacid DR, which had sales of $2.97 billion during the 12-month period ended June 30, according to IMS Health data.
Both companies said they would begin shipping their versions of the drug immediately. The Matrix version will be sold under the Mylan Pharmaceuticals brand.
FDA approves GSK’s nonadjuvant H1N1 vaccine
PHILADELPHIA GlaxoSmithKline on Tuesday announced that the Food and Drug Administration has approved its unadjuvanted influenza A(H1N1) pandemic vaccine.
The U.S. Department of Health and Human Services has placed an order to fill 7.6 million doses of unadjuvanted H1N1 pandemic vaccine from GSK, which will contribute to the approximately 250 million doses secured by the U.S. government. The vaccine will be produced in multi-dose vials from bulk vaccine manufactured at GSK’s facility in Quebec, Canada. GSK expects to begin shipping vaccine in December and to provide all 7.6 million doses by the end of the year.
An adjuvant is a substance added to a vaccine to improve the immune response, however none of the H1N1 vaccines currently approved in the U.S. contain adjuvants.